Compare IGR & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGR | RXST |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 524.6M |
| IPO Year | N/A | 2021 |
| Metric | IGR | RXST |
|---|---|---|
| Price | $4.56 | $9.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.30 |
| AVG Volume (30 Days) | ★ 747.7K | 735.6K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $3.88 | $6.32 |
| 52 Week High | $5.70 | $37.13 |
| Indicator | IGR | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 33.48 |
| Support Level | $4.35 | $10.22 |
| Resistance Level | $4.42 | $13.14 |
| Average True Range (ATR) | 0.07 | 0.60 |
| MACD | 0.05 | -0.31 |
| Stochastic Oscillator | 82.93 | 1.97 |
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.